By the Top Tier Newswire AI Desk · August 10, 2026 at 1:18 PM ET · reviewed against 12 wire stories
ABCELLERA BIOLOGICS (ABCL) is up +43.65% in the latest session. Our newswire has captured 12 stories on ABCL across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABCL stock surged 43.65% to $9.96 on Monday, driven by positive mid-stage clinical trial results for its menopause treatment ABCL635. The biotech company reported that the drug delivered a 50% greater reduction in hot flashes compared to a placebo after a single dose. The trial results, disclosed in an SEC 8-K filing, have sparked significant investor interest and pushed the company’s market cap to $2.0 billion.
What Happened
AbCellera Biologics Inc. announced that its antibody therapy ABCL635 achieved a statistically significant 50% placebo-adjusted reduction in the frequency of moderate-to-severe vasomotor symptoms, including hot flashes. The drug also showed an 83% mean reduction in hot flashes, with favorable tolerability and added sleep benefits. The Phase 2 trial met its primary endpoints, marking a potential breakthrough in non-hormonal menopause treatment. The stock opened with an 8.2% gap up and climbed further throughout the session, reaching an intraday high of $10.00 before closing at $9.96. The unusual options activity included a notable $170K put premium print, indicating some bearish positioning.
What The Data Shows
The stock has risen 57.5% over the last eight sessions, from $5.69 to $8.96, before today’s dramatic move. Intraday volume reached 30.8 million shares, or 4.5 times the 3-month average. The stock is currently trading above its 52-week high of $8.44. Recent insider activity includes a $95K buy by director John S. Montalbano on May 14, 2026. The company remains unprofitable with a TTM EPS of -0.55 and a net margin of -248.8%, but revenue has grown 101.3% TTM.
What To Watch
AbCellera has no scheduled earnings date in the near term. Investors should monitor the breadth of analyst coverage and potential follow-up data from the Phase 2 trial. The company’s ability to advance ABCL635 into later-stage trials will be a key factor in sustaining the current momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABCL · today's session (5-min) · +35.14% vs prior close · updated 3:17 PM ETAI sentiment, last 36h · averaged over 12 stories · 70/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
6h agoBloombergBULLISH 78Product/PR
AbCellera (ABCL) Stock Jumps 41% After Hot Flash Drug Trial Success
Biotech company AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after it said a potential remedy for hot flashes was effective in a mid-stage trial.
7h agoMarketChameleonBULLISH 73Product/PR
ABCL635 Delivers Statistically Significant Phase 2 Results—50% Greater Reduction in Hot Flashes Over Placebo
August 10, 2026
AbCellera’s ABCL635 achieves a notable 50% placebo-adjusted reduction in frequency of moderate-to-severe vasomotor symptoms (hot flashes) after a single dose, marking a landmark in non-hormonal menopause treatment with strong efficacy and tolerability from its Phase 2 clinical trial.
7h agoSeeking AlphaBULLISH 78Product/PR
AbCellera surges on positive mid-stage results for menopause drug ABCL635
AbCellera (ABCL) stock jumps 35% after positive Phase 2 ABCL635 menopause hot flash data, showing strong symptom reductions vs placebo—read the update.
AbCellera (NASDAQ:ABCL) shares surge 22% after ABCL635 meets its Phase 2 endpoints, significantly reducing menopause-related hot flashes and symptom severity.
AbCellera stock surges 22% on positive trial results
AbCellera stock surges 22% on positive trial results
10h agoBarron'sBULLISH 67Product/PR
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.
New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.
11h agoMarketChameleonBULLISH 67Product/PR
ABCL635’s Phase 2 Results Show 83% Mean Reduction in Hot Flashes—A Potential Shift for Menopausal Symptom Relief
August 10, 2026
AbCellera’s antibody therapy ABCL635 delivered a 50% greater reduction in hot flash frequency than placebo in a Phase 2 trial, with added sleep benefits and favorable tolerability. We break down what this could mean for the 12 million US women with moderate-to-severe vasomotor symptoms.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →